MT-2 (Melanotan II)

Is Melanotan 2 Safe? What Has Actually Been Published

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

A published safety literature exists. Reid and colleagues reported atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013, and Eijmael and colleagues reviewed the risks in the Nederlands Tijdschrift voor Geneeskunde in 2022. This is documented clinical concern rather than speculation.

Key facts

Reid 2013
Ir Med J: atypical melanocytic naevi
Eijmael 2022
Ned Tijdschr Geneeskd: risk review
Literature type
Case reports and clinical reviews
Setting
Dermatology
Product type
Unlicensed injectable
Regulatory assessment
None conducted

Why this is stated rather than omitted

An unlicensed injectable compound with published dermatological case reports is a situation where withholding the literature would be the wrong editorial choice. The reports exist in indexed medical journals and are straightforwardly findable. Presenting the compound without them would give an incomplete picture of what is known.

What the case reports describe

Reid and colleagues documented atypical melanocytic naevi appearing following melanotan injection, published in the Irish Medical Journal in 2013. Melanocytic naevi are pigmented lesions, and changes in them are exactly what dermatological surveillance exists to detect. Case reports establish that something was observed and documented in identified patients.

Research material referenced

MT-2 10mg, third-party HPLC tested

Buy MT-2 · £24.99

What a case report can and cannot establish

It establishes an observation. It does not establish causation, incidence or risk, because there is no denominator (no count of how many people used the compound without the outcome). This is the same limitation that applies to pharmacovigilance disproportionality signals, and it cuts both ways: a case report is not proof of harm, and it is not dismissible either.

The 2022 review

Eijmael and colleagues published on the risks of tanning with this compound class in the Nederlands Tijdschrift voor Geneeskunde in 2022. A national medical journal publishing a risk review indicates the clinical community considered the topic worth addressing directly.

Why an unlicensed injectable is a distinct category of concern

No regulator has assessed this compound's safety, so there is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist simply does not. What is available instead is what individual clinicians have chosen to publish after seeing something.

What is claimed here

Nothing about what this compound does or does not do in any person. This article reports that a published safety literature exists and what it contains. Material supplied here is for laboratory research only.

Frequently asked questions

What are the side effects of Melanotan 2?

The literature reports nausea, facial flushing, spontaneous erections and, most significantly, changes to existing naevi (moles darkening, enlarging or becoming atypical), with case reports linking melanotan use to melanoma. These come from case reports and small series, not controlled trials.

Does Melanotan 2 change eye colour?

Iris darkening is reported anecdotally and is biologically plausible, since the iris contains melanocytes expressing melanocortin receptors. It is not documented in controlled studies, and any such change would not be expected to reverse.

Is Melanotan 2 permanent?

Pigmentation is not permanent. Melanin is lost as skin cells turn over, so it fades over weeks once the stimulus stops. Changes to moles are a different matter and are not assumed to reverse.

Is there published safety literature on MT-2?

Yes: case reports of atypical melanocytic naevi following injection in the Irish Medical Journal in 2013, and a 2022 risk review in a Dutch medical journal.

Do case reports prove harm?

No. They establish an observation without a denominator, so they cannot establish causation or incidence. They are also not dismissible.

Why does unlicensed status matter for safety?

There is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist does not.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More MT-2 (Melanotan II) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.